Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Torrent Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
NSE:TORNTPHARM'
s EV-to-EBIT Range Over the Past 10 Years
Min: 13.54 Med: 28.13 Max: 61.28
Current: 60.7
During the past 13 years, the highest EV-to-EBIT of Torrent Pharmaceuticals was 61.28. The lowest was 13.54. And the median was 28.13.
NSE:TORNTPHARM's EV-to-EBIT is ranked worse than 87.26% of 683
companies
in the Drug Manufacturers industry
Industry Median: 16.14
vs NSE:TORNTPHARM: 60.70
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Torrent Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was ₹1,757,338 Mil.
Torrent Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹35,010 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Torrent Pharmaceuticals EV-to-EBIT Related Terms
Torrent Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Torrent Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Torrent Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Torrent Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Torrent Pharmaceuticals's EV-to-EBIT falls into.
Torrent Pharmaceuticals's current Enterprise Value is ₹2,125,071 Mil.
Torrent Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹35,010 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Torrent Pharmaceuticals (NSE:TORNTPHARM) has a EV-to-EBIT of 60.70 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Torrent Pharmaceuticals and its competitors. This is 116% above median its historical median of 28.13. Over the past decade, Torrent Pharmaceuticals' EV-to-EBIT has ranged from 13.54 to 61.28. According to the industry distribution chart, Torrent Pharmaceuticals ranks #596 out of 683 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is Torrent Pharmaceuticals' EV-to-EBIT too high?
Torrent Pharmaceuticals' current EV-to-EBIT of 60.70 is 116% above median its 10-year median of 28.13. Over the past 10 years, this metric has ranged from a low of 13.54 to a high of 61.28. The Drug Manufacturers industry median EV-to-EBIT is 16.14. Torrent Pharmaceuticals' value of 60.70 is 276.1% above this industry median. Based on the distribution chart, Torrent Pharmaceuticals ranks #596 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Torrent Pharmaceuticals has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Torrent Pharmaceuticals' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Torrent Pharmaceuticals ranks #596 out of 683 companies for EV-to-EBIT. This places Torrent Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 16.14. Torrent Pharmaceuticals' value of 60.70 is 276.1% above this benchmark. Historically, Torrent Pharmaceuticals' own EV-to-EBIT has ranged from 13.54 to 61.28 over the past decade. While the company's 10-year median is 28.13 vs. the industry median of 16.14, Torrent Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.14, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Torrent Pharmaceuticals's current EV-to-EBIT of 60.70 is 276.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Torrent Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Torrent Pharmaceuticals's current EV-to-EBIT is 60.70, which is 116% above median its own 10-year median of 28.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Torrent Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Torrent Pharmaceuticals (NSE:TORNTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹4,608.87, compared to a current price of ₹5,012.00 — trading 8.7% above its estimated fair value. The current EV-to-EBIT is 60.70, which is 116% above median its 10-year median of 28.13 and 276.1% above the Drug Manufacturers industry median of 16.14. Torrent Pharmaceuticals' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Torrent Pharmaceuticals (NSE:TORNTPHARM), the current EV-to-EBIT is 60.70 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Torrent Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹5,012.00 is trading 8.7% above its estimated GF Value™ of ₹4,608.87.
GuruFocus considers Torrent Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:TORNTPHARM:
EV-to-EBIT: 60.70 (116% above median its 10-year median of 28.13)
GF Value™: ₹4,608.87 vs. price of ₹5,012.00 (8.7% above fair value)
Industry Position: 276.1% above the Drug Manufacturers median (#596 of 683)
No single metric tells the full story. See the NSE:TORNTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, Vitamins Minerals Nutrients (VMN), and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.
88GF Score
Get the complete analysis for NSE:TORNTPHARM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TORNTPHARM has been successfully added to your 
